Navigation Links
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Date:2/16/2012

KING OF PRUSSIA, Pa., Feb. 16, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX. CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX: CSL).

The CSL Behring rVIIa-FP clinical program will soon be initiated and intends to demonstrate that an extended half-life rVIIa-FP will result in a requirement for fewer doses while providing adequate therapeutic response in patients who have hemophilia A and B with inhibitors.

"CSL Behring's albumin fusion technology uses albumin as the ideal recombinant genetic fusion partner for coagulation factor proteins because of its high tolerability, inherently long half-life, low potential for immunogenic reactions and known mechanism of clearance," said Russell Basser, M.D., Senior Vice President, Global Clinical R&D at CSL Behring. "CSL Behring's rVIIa albumin fusion protein is expected to exhibit a good tolerability profile and improved pharmacokinetics that may enable prophylaxis. We welcome Orphan Drug Designation for our rVIIa-FP and will work closely with the FDA to make this important therapy available for people in the U.S. with hemophilia A and hemophilia B with inhibitors."

The FDA's Orphan Drug Designation program provides orphan status to unique drugs and biologics, defined as those intended for the safe and effective treatment or prevention of rare dise
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
2. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
3. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
4. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
9. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
10. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... June 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... neuroblocking technology to treat obesity, metabolic diseases, and other ... public offering  of 40,229,886 units. Each unit consists of ... A warrant to purchase one share of common stock, ... one share of common stock, at a purchase price ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... YONKERS, N.Y., Sept. 27, 2011 As a result ... that could be dangerous to their health, according to ... Americans who currently take a prescription medicine told pollsters ... a doctor,s visit or medical procedure, declining tests, or ...
... Pa., Sept. 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of synthetic immunogens against cancers and infectious diseases, ... Research and Development Agreement (CRADA) with the United States ... Plum Island Animal Disease Center. This collaboration will evaluate ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... a $3.1 million grant to study how sensory stimuli can be used to “decrease ... on improving care for children with autism, will compare patient experience in a “typical ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... eyeglasses online , finally its here, http://www.express-glasses.com is proud ... rates, for many location, ask about shipping with DHL Express when calling or ...
(Date:6/30/2015)... ... 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of ... a new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus ... customers have come to know and respect for over eight years. , “I am ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... manager of HRA Healthcare Research & Analytics , a consultative healthcare market ... Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and multi-client ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... Digest discussed the advantages that fat transfer procedures had over breast implants ... fat transfer techniques create breasts that “look and feel natural,” have increased sensation, ...
Breaking Medicine News(10 mins):Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Institute (BBRI) and the University of Pennsylvania have found ... green tea component EGCG, can prevent and destroy ... are the primary culprits in fatal brain disorders such ... published in the current issue of Nature Chemical ...
... Vaccine protected volunteers from virus linked to cervical cancer , ... vaccine Cervarix protects women from infection for longer than six ... the two types of HPV (HPV-16 and HPV-18) most commonly ... 800 women, aged 15 to 25, with a normal cervical ...
... cut risk factors linked to diabetes, cardiovascular trouble, , ... for just a couple of months, can significantly lower ... cluster of heart disease risk factors -- years later, ... the journal Diabetes . , In women who ...
... ... the iPhone or iPod touch. Pop up menu’s and one touch exporting keeps track of and ... ... new iPhone application for surgery, can be used by surgeons, residents, surgical interns, medical students, and ...
... ... as increase the risk of obesity. Treadmill desks have been show effective in lowering ... ... 2009 -- Two sleep studies illustrating the negative effects of sleep deprivation on the ...
... ... people to sanitize their hands anytime, anywhere, is now available. , ... (PRWEB) December 3, 2009 -- It still blazes across ... of stories about the spread of H1N1 influenza A (swine flu) . Reports of ...
Cached Medicine News:Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 3Health News:Treadmill Desks Lower Health Risks Caused by Lack of Sleep 2Health News:Finally, Some Good News about Swine Flu 2
... Integra II SP MRI-Compatible Anesthesia System is perfect ... more than one type of anesthetic agent. ... and due to its wider stance, has a ... ventilator bellows assembly is utilized in both the ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... PURPLE NITRILE* product family offers a comprehensive ... gloves were designed as an alternative for ... hypersensitivity to natural rubber latex proteins. The ... from latex and other synthetic gloves. Custom ...
... and the distinctive COLOR PURPLE* distinguish ... them for sterile clinical procedures when ... required. Theyre designed as an alternative ... Type 1 hypersensitivity to natural rubber ...
Medicine Products: